Long-term sustainability of glycaemic achievements with second-line anti-diabetic therapies in patients with type 2 diabetes: A real-world study

Further Publications

What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated HbA1c (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER study

Diabetes Obes Metab

Bonnet F, Chen H, Cooper A, Gomes MB, Ji L, Leigh P, Gutierrez LR, Shestakova MV, Shimomura I, Siddiqui A, Tang F, Vora J, Watada H, Khunti K

doi: 10.1111/dom.14476

COMMENTED

Type 2 Diabetes

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: results from the global DISCOVER study programme

Diabetes Obes Metab.

Nicolucci A, Charbonnel B, Gomes MB, Khunti K, Kosiborod M, Shestakova MV, Shimomura I, Watada H, Chen H, Cid-Razufa J, Fenici P, Hammar N, Surmont F, Tang F, Pocock S

doi: 10.1111/dom.13830.

COMMENTED

Diabetes - GeneralType 2 Diabetes

Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes

Diabetes Care.

Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK

doi: 10.2337/dc17-1414.

COMMENTED

Diabetes - GeneralType 2 Diabetes

Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes

Diabetes Care.

Carls GS, Tuttle E, Tan RD, Huynh J, Yee J, Edelman SV, Polonsky WH

doi: 10.2337/dc16-2725.

COMMENTED

Diabetes - General

Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus

Ann Intern Med.

Roglic G, Norris SL

doi: 10.7326/M18-1149.

Diabetes - GeneralType 2 Diabetes

Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1RA and DPP4 Therapies in Patients With Type 2 Diabetes

Diabetes Care.

Carls GS, Tuttle E, Tan RD, Huynh J, Yee J, Edelman SV, Polonsky WH

doi: 10.2337/dc16-2725.

Type 2 Diabetes

Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg Study

Ann Med.

Pérez-Belmonte LM, Osuna-Sánchez J, Millán-Gómez M, López-Carmona MD, Gómez-Doblas JJ, Cobos-Palacios L, Sanz-Cánovas J, Barbancho MA, Lara JP, Jiménez-Navarro M, Bernal-López MR, Gómez-Huelgas R

doi: 10.1080/07853890.

COMMENTED

Type 2 Diabetes

Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes

JAMA Netw Open.

O’Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N, Moran MR, Liss DT, Prospect TA, Ackermann RT

doi: 10.1001/jamanetworkopen.

COMMENTED

Type 2 Diabetes

Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Lancet Diabetes Endocrinol.

Griffin SJ, Rutten GEHM, Khunti K, Witte DR, Lauritzen T, Sharp SJ, Dalsgaard EM, Davies MJ, Irving GJ, Vos RC, Webb DR, Wareham NJ, Sandbæk A

doi: 10.1016/S2213-8587(19)30349-3.

Related content

What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated HbA1c (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER study

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: results from the global DISCOVER study programme

Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes

Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes

Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1RA and DPP4 Therapies in Patients With Type 2 Diabetes

Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg Study

Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes

Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial